Interpace Diagnostics Group Stock News

In a report released today, Jason McCarthy from Maxim Group assigned a Buy rating to Immutep (IMMP – Research Report),

In a report released yesterday, Kevin DeGeeter from Oppenheimer maintained a Buy rating on Athenex (ATNX), with a price target of $23.00. The company's

In a report released yesterday, Kevin DeGeeter from Oppenheimer maintained a Buy rating on Athenex (ATNX – Research Report), with

Maxim Group analyst Jason McCarthy assigned a Buy rating to Atossa Genetics (ATOS) today and set a price target of $4.00. The company's shares closed last

Maxim Group analyst Jason McCarthy assigned a Buy rating to Atossa Genetics (ATOS – Research Report) today and set a

We highlight main points from Roche Q1 conference call and summarize key takeaways for investors. Pharma is showing resilience in the face of intensive biosimil

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Selecta Biosciences (SELB), CytoDyn (CYDY) and Sutro

Interpace Biosciences (IDXG) announced today that its subsidiary, Interpace Diagnostics, has entered into a contract with Avalon Healthcare Solutions (Avalon), a specialty benefit management company w

all Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Arch Coal, Glacier Bancorp and IHS Markit on Monday. HIGHLIGHTS * Arch

Interpace Diagnostics Group (NASDAQ:IDXG)‘s stock had its “buy” rating restated by stock analysts at Maxim Group in a note issued to investors on Friday, AnalystRatings.com reports. They current

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on CareDx (CDNA) today and set a price target of $43.00. The company's shares closed last Thursday

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on CareDx ( CDNA – Research Report ) today and set a price target of $43.00 . The company’s shares closed last Thursday at $24.08. According

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.11%

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Interpace Diagnostics Group (IDXG) and Principia Biopharma

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Immunomedics (IMMU), Interpace Diagnostics Group (IDXG) and